Ongoing Strategic Partnership with Merck: The company maintains a high-value collaboration with Merck & Co. to develop α7 receptor modulators for cognitive dysfunction. This partnership has provided significant milestone payments, including approximately $15 million in 2025, which extended the company's financial runway into late 2026.